5 mg (N=6) 5 mg (N=6) 15 mg (N=6) 15 mg (N=6) 40 mg (N=6) 40 mg (N=6) 80 mg (N=6) 80 mg (N=6) 120 mg (N=5) 120 mg (N=5) 160 mg (N=1) 160 mg (N=1) Placebo (N=12) Placebo (N=12)
n (%) m n (%) m n (%) m n (%) m n (%) m n (%) m n (%) m
Infections and infestations 3 (50.0%) 3 1 (16.7%) 1 1 (16.7%) 1 1 (16.7%) 1 1 (20.0%) 1 0 0 2 (16.7%) 2
  Nasopharyngitis 3 (50.0%) 3 1 (16.7%) 1 1 (16.7%) 1 1 (16.7%) 1 1 (20.0%) 1 0 0 2 (16.7%) 2
Nervous system disorders 1 (16.7%) 1 2 (33.3%) 2 0 0 1 (16.7%) 1 1 (20.0%) 2 1 (100%) 3 2 (16.7%) 2
  Headache 1 (16.7%) 1 2 (33.3%) 2 0 0 1 (16.7%) 1 1 (20.0%) 1 0 0 2 (16.7%) 2
  Disturbance in attention 0 0 0 0 0 0 0 0 1 (20.0%) 1 1 (100%) 1 0 0
  Dizziness 0 0 0 0 0 0 0 0 0 0 1 (100%) 1 0 0
  Tremor 0 0 0 0 0 0 0 0 0 0 1 (100%) 1 0 0
Gastrointestinal disorders 0 0 2 (33.3%) 2 0 0 0 0 0 0 0 0 1 (8.3%) 1
  Gastrointestinal hypermotility 0 0 1 (16.7%) 1 0 0 0 0 0 0 0 0 0 0
  Toothache 0 0 0 0 0 0 0 0 0 0 0 0 1 (8.3%) 1
  Vomiting 0 0 1 (16.7%) 1 0 0 0 0 0 0 0 0 0 0
Psychiatric disorders 0 0 0 0 0 0 0 0 1 (20.0%) 1 1 (100%) 2 0 0
  Restlessness 0 0 0 0 0 0 0 0 1 (20.0%) 1 1 (100%) 1 0 0
  Nervousness 0 0 0 0 0 0 0 0 0 0 1 (100%) 1 0 0
Respiratory, thoracic and mediastinal disorders 1 (16.7%) 1 1 (16.7%) 1 0 0 0 0 0 0 0 0 1 (8.3%) 2
  Oropharyngeal pain 0 0 1 (16.7%) 1 0 0 0 0 0 0 0 0 1 (8.3%) 1
  Cough 0 0 0 0 0 0 0 0 0 0 0 0 1 (8.3%) 1
  Epistaxis 1 (16.7%) 1 0 0 0 0 0 0 0 0 0 0 0 0
Skin and subcutaneous tissue disorders 0 0 1 (16.7%) 1 0 0 0 0 0 0 1 (100%) 1 0 0
  Cold sweat 0 0 0 0 0 0 0 0 0 0 1 (100%) 1 0 0
  Eczema 0 0 1 (16.7%) 1 0 0 0 0 0 0 0 0 0 0
Metabolism and nutrition disorders 0 0 0 0 1 (16.7%) 1 0 0 0 0 0 0 0 0
  Decreased appetite 0 0 0 0 1 (16.7%) 1 0 0 0 0 0 0 0 0
Musculoskeletal and connective tissue disorders 0 0 0 0 0 0 0 0 0 0 0 0 1 (8.3%) 1
  Back pain 0 0 0 0 0 0 0 0 0 0 0 0 1 (8.3%) 1